Study Close Out & Reporting

Home / CRO / Study Close Out & Reporting
Planning & Preparation Trial Initiation Patient Recruitment, Enrollment & Retention Trial Execution & Monitoring Data Management & Analysis Study Close Out & Reporting

Finalising Clinical Trials with Precision and Purpose

As a clinical trial reaches its conclusion, the Study Close-Out & Reporting phase ensures all regulatory, operational, and scientific requirements are met. This stage involves final data lock, regulatory submissions, clinical research site closure activities, and comprehensive reporting of trial outcomes.

Proper documentation and analysis are crucial for compliance and future research, paving the way for potential treatment approvals and medical advancements. A well-executed close-out ensures the integrity and impact of the study’s findings.

Key tasks

Close-Out Site Visits & Audits

WEP expertly manages close-out site monitoring visits and audits at the end of a clinical trial to ensure all data is finalized, regulatory compliance is met, and site responsibilities are properly closed. Our process follows Good Clinical Practice (GCP) and regulatory guidelines (FDA, EMA, MHRA, etc.).
Learn more

Final Report Submission to Regulatory Authorities

This is an important step towards ensuring full compliance, data integrity, and readiness for audits or future reference. WEP expertly manages this to help Sponsors successfully avoid delays, regulatory rejection, legal liabilities, and loss of valuable data.
Learn more

Publish Clinical Trial Results

Publishing clinical trial findings in medical journals and presenting data at conferences are both essential for scientific validation, transparency, and advancing medical knowledge. Peer-reviewed publications ensure credibility, while conference presentations facilitate discussions with experts and key opinion leaders.

Additionally, sharing results enhances a company’s reputation, attracts investors, and enables the inclusion of findings in meta-analyses that shape future treatments. WEP can help spearhead these efforts on behalf of the Sponsor.

Learn more

Post-Marketing Surveillance

Regulatory submission marks the end of the clinical trial phase and the start of post-marketing surveillance – Phase IV studies. At WEP, we specialize in managing Phase 4 clinical studies that generate real-world evidence, assess long-term safety, and support post-marketing commitments. Our expertise ensures that your therapy achieves sustained success beyond regulatory approval, helping you maximize its value in the marketplace.
Learn more

Need more information?

Get in touch